MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s40164-024-00557-9

Медицинская библиотека · Experimental hematology & oncology · 2024

Application patterns and outcomes of hematopoietic stem cell transplantation in peripheral T-cell lymphoma patients: a multicenter real-world study in China.

Gao Hongye, Zhang Zhuoxin, Wang Jiali, Jia Yannan, Zheng Yawei, Pei Xiaolei, Zhai Weihua, Zhang Rongli, Chen Xin, Ma Qiaoling, Wei Jialin, Yang Donglin, Pang Aiming, He Yi, Feng Sizhou, Zhang Hao, Du Xin, Song Xianmin, Liu Yao, Zou Dehui, Jiang Erlie

Письмо в редакциюПеревод в очереди

Аннотация

The optimal timing and type of hematopoietic stem cell transplantation (HSCT) for treating peripheral T-cell lymphoma (PTCL) remain controversial. This retrospective real-world study investigated the application pattern and outcomes of HSCT in China. The analysis encompassed 408 PTCL patients with a median age of 45.5 years, all of whom received initial adequate therapy at five hospitals. Among patients with nodal PTCL who responded effectively to first-line therapy (the "responders", n = 127) and subsequently underwent HSCT consolidation (n = 47, 37.0%), 93.6% received auto-HSCT, while 6.4% underwent allo-HSCT. Front-line auto-HSCT showed potential for long-term disease control in nodal PTCL responders. Among non-nodal PTCL responders (n = 80) with HSCT (n = 26, 32.5%), 46.2% underwent allo-HSCT and 53.8% received auto-HSCT. Upfront allo-HSCT provides longer progression-free survival (PFS) for non-nodal PTCL responders, with lower 3-year cumulative incidence of relapse (CIR) (16.7% vs. 56.0%) and comparable non-relapse mortality (NRM) (10.4% vs. 11.0%) compared to auto-HSCT. For patients who achieved remission with second-line salvage regimens, allo-HSCT was the primary choice (82.4%) for non-nodal PTCL, while auto-HSCT was more common (82.4%) in nodal PTCL. Nodal PTCL patients underwent auto-HSCT after ≥ 3 lines of treatment had a higher 3-year CIR (81.0%) compared to those treated in the first (26.0%) or second line (26.0%). Non-nodal PTCL patients underwent allo-HSCT after ≥ 3 lines had a higher 3-year NRM (37.5%) compared to after first (10.4%) or second line treatment (8.5%). These findings highlight distinct HSCT application patterns for PTCL in China, emphasizing the impact of early disease control and upfront consolidative HSCT.

Для цитирования: Gao Hongye, Zhang Zhuoxin, Wang Jiali, Jia Yannan, Zheng Yawei, Pei Xiaolei, Zhai Weihua, Zhang Rongli, Chen Xin, Ma Qiaoling, Wei Jialin, Yang Donglin, Pang Aiming, He Yi, Feng Sizhou, Zhang Hao, Du Xin, Song Xianmin, Liu Yao, Zou Dehui, Jiang Erlie. Application patterns and outcomes of hematopoietic stem cell transplantation in peripheral T-cell lymphoma patients: a multicenter real-world study in China.. Experimental hematology & oncology. 2024. DOI: 10.1186/s40164-024-00557-9.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.